Swiss National Bank Has $210.45 Million Holdings in Elevance Health, Inc. $ELV

Swiss National Bank cut its position in shares of Elevance Health, Inc. (NYSE:ELV) by 5.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 651,300 shares of the company’s stock after selling 34,000 shares during the period. Swiss National Bank owned about 0.29% of Elevance Health worth $210,448,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nilsine Partners LLC increased its holdings in Elevance Health by 1.5% in the 3rd quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after buying an additional 29 shares during the period. HBK Sorce Advisory LLC lifted its holdings in shares of Elevance Health by 4.4% during the 3rd quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after acquiring an additional 31 shares during the period. Detalus Advisors LLC lifted its holdings in shares of Elevance Health by 1.8% during the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock worth $558,000 after acquiring an additional 31 shares during the period. Forum Financial Management LP boosted its position in shares of Elevance Health by 1.1% during the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after acquiring an additional 33 shares in the last quarter. Finally, Activest Wealth Management increased its stake in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after acquiring an additional 34 shares during the period. 89.24% of the stock is owned by institutional investors.

Elevance Health Trading Down 3.1%

Shares of ELV stock opened at $280.80 on Tuesday. The company has a market capitalization of $61.98 billion, a P/E ratio of 11.18, a P/E/G ratio of 1.60 and a beta of 0.51. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a 50-day moving average price of $343.29 and a 200 day moving average price of $335.14.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the prior year, the firm earned $3.84 earnings per share. The company’s quarterly revenue was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Research analysts forecast that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $6.88 dividend on an annualized basis and a yield of 2.5%. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s payout ratio is 27.23%.

Wall Street Analyst Weigh In

ELV has been the subject of several recent research reports. TD Cowen reissued a “buy” rating on shares of Elevance Health in a research report on Wednesday, November 26th. JPMorgan Chase & Co. lifted their price objective on Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a report on Monday, February 2nd. Wells Fargo & Company dropped their target price on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a report on Friday, January 30th. Guggenheim cut their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a research report on Thursday, January 29th. Finally, UBS Group set a $400.00 price target on Elevance Health in a research note on Thursday, January 29th. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.